Crohn’s Disease (Regional Enteritis) - Pipeline Review, H1 2016

Crohn’s Disease (Regional Enteritis) - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack.
This report provides comprehensive information on the therapeutics under development for Crohn’s Disease (Regional Enteritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crohn’s Disease (Regional Enteritis) and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ Crohn’s Disease (Regional Enteritis) - Pipeline Review, H1 2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Crohn’s Disease (Regional Enteritis)
- The report reviews pipeline therapeutics for Crohn’s Disease (Regional Enteritis) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Crohn’s Disease (Regional Enteritis) therapeutics and enlists all their major and minor projects
- The report assesses Crohn’s Disease (Regional Enteritis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Crohn’s Disease (Regional Enteritis)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Crohn’s Disease (Regional Enteritis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Crohn’s Disease (Regional Enteritis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

4D Pharma Plc 4SC AG AB Science SA AbbVie Inc. Alfa Wassermann S.p.A Amgen Inc. Ampio Pharmaceuticals, Inc. Arena Pharmaceuticals, Inc. Avaxia Biologics, Inc. BioAtla, LLC BIOCAD BioLingus AG Bionovis SA BioTherapeutics Inc. Boehringer Ingelheim GmbH Calypso Biotech SA Celgene Corporation Celltrion, Inc. ChemoCentryx, Inc. ChironWells GmbH Chong Kun Dang Pharmaceutical Corp. CLL Pharma Commence Bio, Inc. Daiichi Sankyo Company, Limited DBV Technologies S.A. Effimune SAS Eisai Co., Ltd. Eli Lilly and Company Enterome Bioscience SA Enzo Biochem, Inc. Epirus Biopharmaceuticals, Inc. Ferring International Center S.A. Galapagos NV Genentech, Inc. Genfit SA Genor BioPharma Co., Ltd. Gilead Sciences, Inc. Idera Pharmaceuticals, Inc. Immune Response BioPharma, Inc. Inbiopro Solutions Pvt. Ltd. Innovate Biopharmaceuticals, Inc. Innovent Biologics, Inc. Johnson & Johnson Jyant Technologies, Inc. Kineta, Inc. Kymab Limited Kyorin Pharmaceutical Co., Ltd. Mabion SA MedImmune, LLC Mesoblast Limited Mitsubishi Tanabe Pharma Corporation Momenta Pharmaceuticals, Inc. Mycenax Biotech Inc. Neovacs SA Ocata Therapeutics, Inc. Oncobiologics, Inc. Oncodesign SA Pfenex Inc. Pfizer Inc. Pluristem Therapeutics Inc. Protagonist Therapeutics Inc. Protalix BioTherapeutics, Inc. Qu Biologics Inc. Re-Pharm Limited Receptos, Inc. RedHill Biopharma Ltd. SATT Nord Selexys Pharmaceuticals Corporation Sigmoid Pharma Limited Soligenix, Inc. Stelic Institute & Co., Inc. Sylentis S.A.U. TaiwanJ Pharmaceuticals Co., Ltd. Takeda Pharmaceutical Company Limited Therapeutic Proteins International, LLC Tiziana Life Sciences PLC Toray Industries, Inc. Trino Therapeutics Limited TxCell SA Ventria Bioscience Virobay Inc. Xbrane Biopharma AB


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###